Omicron variant
THE following is a summary of some recent studies on COVID-19. They include research that warrants further study to corroborate the findings and that has yet to be certified by peer review.
Coronavirus leaves survivors with self-attacking antibodies
Months after recovering from SARSCoV-2 infection, survivors have elevated levels of antibodies that can mistakenly attack their own organs and tissues, even if they had not been severely ill, according to new findings.
Among 177 healthcare workers who had recovered from confirmed coronavirus infections contracted before the availability of vaccines, all had persistent autoantibodies, including ones that can cause chronic inflammation and injury of the joints, skin and nervous system.
“We would not normally expect to see such a diverse array of autoantibodies elevated in these individuals or stay elevated for as long six months after full clinical recovery,” said Susan Cheng of the CedarsSinai Smidt Heart Institute in Los Angeles.
Patterns of elevated autoantibodies varied between men and women, the researchers reported on Thursday in the Journal of Translational Medicine.
“We don’t yet know how much longer, beyond six months, the antibodies will stay elevated and/or lead to any important clinical symptoms,” Cheng said.
“It will be essential to monitor individuals moving forward.”
Her team is investigating whether autoantibody elevations are linked with persistent symptoms in people with long COVID and planning to study autoantibody levels after infections with newer variants of the virus.
The effects of antibodies produced by the immune system’s “memory B cells” against the Omicron variant of the coronavirus, while weakened, could still be significant, researchers believe.
Once the body learns to recognise SARS-CoV-2, either after infection or vaccination, B cells generate fresh antibodies against the virus if there are not already enough antibodies circulating in the blood that can neutralise it.
In a study reported on bioRxiv ahead of peer review, researchers analysed the strength of more than 300 antibodies produced by memory B cells obtained from vaccinated volunteers, including some who had a prior SARS-CoV-2 infection.
“Omicron seemed to evade a very large share of the memory B cells pool,” researchers said, adding that it “seems to still be efficiently recognised by 30 per cent of total antibodies and close to 10 per cent of all potent neutralising antibodies,” said Matthieu Mahevas and Pascal Chappert of Universite de Paris in a joint email.
Memory B cells’ robust ability to proliferate and produce antibodies might compensate “in less than two days” for those antibodies’ reduced effectiveness, they speculate.
In combination with other immune system components, particularly T cells, the effects of B cells likely help to explain why most vaccinated individuals who become infected do not become sick enough to require hospitalization, they said. Virus variants’ activity in cells makes them more effective
Along with spike mutations that help the coronavirus break into cells, mutations that change how the virus behaves inside the cells are a big factor in why some variants have been more transmissible, researchers have discovered.
The findings, published in Nature, show that scientists “have to start looking at mutations outside the spike,” which has so far been the main focus of vaccines and antibody drugs, said Nevan Krogan of the University of California, San Francisco.
Studying the Alpha variant, his team found a mutation at a non-spike site that causes infected cells to ramp up their production of a protein called Orf9B. Orf9b in turn disables a protein called TOM70 that cells use to send signals to the immune system.
With higher levels of Orf9B disabling TOM70, the immune system does not respond as well and the virus can better evade detection, the researchers said.
Referring to the increase in Orf9B, Krogan said: “It’s rare that mutations ‘turn up’ a protein. It’s a very sneaky thing for this virus to do”.
The same mutation was identified on Delta, “and sure enough, almost the same mutation is on Omicron,” he said, which suggests they may have similar effects on the immune system.
The new information could spur development of drugs that target the interaction of Orf9b and TOM70.
NANCY LAPID is the editor-in-charge of Reuters Health. The views expressed in this article are not necessarily shared by this newspaper.